Insider Selling: ICU Medical, Inc. (NASDAQ:ICUI) CEO Sells 12,000 Shares of Stock

ICU Medical, Inc. (NASDAQ:ICUI) CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the transaction, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $18,665,666.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Vivek Jain also recently made the following trade(s):

• On Tuesday, September 3rd, Vivek Jain sold 12,000 shares of ICU Medical stock. The stock was sold at an average price of $163.46, for a total value of $1,961,520.00.
• On Friday, August 16th, Vivek Jain sold 12,000 shares of ICU Medical stock. The shares were sold at an average price of $156.04, for a total transaction of $1,872,480.00.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $180.38 on Thursday. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.41 and a quick ratio of 1.08. The stock has a market capitalization of $4.40 billion, a P/E ratio of -73.62 and a beta of 0.65. The business has a 50-day moving average of $157.00 and a two-hundred day moving average of $125.33. ICU Medical, Inc. has a fifty-two week low of $78.28 and a fifty-two week high of $188.53.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 EPS for the quarter, topping the consensus estimate of $1.00 by $0.56. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The firm had revenue of $596.50 million for the quarter, compared to the consensus estimate of $556.64 million. During the same quarter last year, the firm posted $1.58 EPS. The business’s quarterly revenue was up 8.6% on a year-over-year basis. On average, equities research analysts predict that ICU Medical, Inc. will post 3.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ICUI has been the topic of several research analyst reports. KeyCorp lifted their price target on ICU Medical from $136.00 to $147.00 and gave the company an “overweight” rating in a research report on Thursday, August 8th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research report on Thursday, August 8th. Raymond James raised their price objective on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. Finally, StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Thursday, September 12th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $149.00.

Institutional Investors Weigh In On ICU Medical

Hedge funds have recently modified their holdings of the business. Motco bought a new position in shares of ICU Medical during the 1st quarter worth about $29,000. Innealta Capital LLC acquired a new position in shares of ICU Medical in the 2nd quarter worth approximately $32,000. GAMMA Investing LLC raised its stake in ICU Medical by 75.1% during the first quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier’s stock worth $33,000 after acquiring an additional 133 shares in the last quarter. EntryPoint Capital LLC lifted its holdings in ICU Medical by 731.5% during the 1st quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock valued at $48,000 after purchasing an additional 395 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of ICU Medical by 46.4% during the first quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 173 shares in the last quarter. 96.10% of the stock is owned by institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.